Incyte Corporation (NASDAQ:INCY) EVP Steven H. Stein sold 2,111 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $125.00, for a total value of $263,875.00. Following the completion of the transaction, the executive vice president now owns 18,687 shares in the company, valued at $2,335,875. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Incyte Corporation (INCY) traded down 0.62% during trading on Thursday, reaching $137.41. The company had a trading volume of 3,812,634 shares. The firm’s 50 day moving average is $129.05 and its 200 day moving average is $129.60. The company’s market capitalization is $28.27 billion. Incyte Corporation has a one year low of $77.58 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The company had revenue of $326.40 million for the quarter, compared to the consensus estimate of $318.45 million. During the same period in the previous year, the firm earned $0.18 earnings per share. The company’s revenue was up 32.5% compared to the same quarter last year. On average, equities research analysts predict that Incyte Corporation will post ($0.86) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Steven H. Stein Sells 2,111 Shares of Incyte Corporation (INCY) Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/steven-h-stein-sells-2111-shares-of-incyte-corporation-incy-stock/1534831.html.

INCY has been the topic of a number of research analyst reports. BMO Capital Markets restated an “outperform” rating and issued a $172.00 target price on shares of Incyte Corporation in a research note on Monday. Morgan Stanley restated an “overweight” rating and issued a $142.00 target price on shares of Incyte Corporation in a research note on Friday, May 19th. Zacks Investment Research upgraded Incyte Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, May 23rd. BidaskClub upgraded Incyte Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, TheStreet lowered Incyte Corporation from a “c+” rating to a “d+” rating in a research note on Thursday, May 4th. Eight analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Incyte Corporation presently has an average rating of “Buy” and an average price target of $140.16.

Large investors have recently modified their holdings of the company. Pillar Pacific Capital Management LLC boosted its stake in shares of Incyte Corporation by 41.0% in the first quarter. Pillar Pacific Capital Management LLC now owns 5,850 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 1,700 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Incyte Corporation by 13.0% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 524,635 shares of the biopharmaceutical company’s stock worth $70,128,000 after buying an additional 60,219 shares in the last quarter. Tyers Asset Management LLC acquired a new position in Incyte Corporation during the first quarter worth approximately $456,000. Great West Life Assurance Co. Can boosted its position in Incyte Corporation by 32.3% in the first quarter. Great West Life Assurance Co. Can now owns 162,133 shares of the biopharmaceutical company’s stock worth $21,660,000 after buying an additional 39,589 shares in the last quarter. Finally, Geneva Advisors LLC acquired a new position in Incyte Corporation during the first quarter worth approximately $1,102,000. 91.04% of the stock is currently owned by institutional investors.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.